Brief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
10/01/2024 13:11
Jan 10 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* EUROPEAN COMMISSION APPROVES KRAZATI (ADAGRASIB) AS A
TARGETED
TREATMENT OPTION FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG
CANCER (NSCLC) WITH A KRASG12C MUTATION
* MIRATI THERAPEUTICS INC- CONDITIONAL MARKETING
AUTHORIZATION FOR
KRAZATI IS VALID IN ALL 27 EU MEMBER STATES PLUS ICELAND, NORWAY
AND LIECHTENSTEIN
Source text for Eikon: ID:nPnb7MXfna
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)